Adlai Nortye (ANL) Total Non-Current Liabilities (2022 - 2026)
Adlai Nortye (ANL) posted quarterly Total Non-Current Liabilities of $1.1 million for Q4 2025, up 165.18% year-over-year from $425000.0 in Q4 2024, and up 338.52% quarter-over-quarter from $257000.0 in Q2 2025.
Analysis
Adlai Nortye (ANL) Total Non-Current Liabilities (2022 - 2026) Analysis & Trends
Adlai Nortye (ANL) has reported Total Non-Current Liabilities for 4 consecutive years, with $1.1 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Total Non-Current Liabilities rose 165.18% year-over-year to $1.1 million; the TTM figure through Dec 2025 stood at $1.1 million (up 165.18% YoY), while the FY2025 annual figure was $1.1 million, up 165.18% from the prior year.
- Total Non-Current Liabilities improved to $1.1 million in Q4 2025 per ANL's latest filing, from $257000.0 in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $5.5 million in Q4 2023 and bottomed at $257000.0 in Q2 2025.
- Historically, Total Non-Current Liabilities has averaged $1.7 million across 4 years, with a median of $1.1 million in 2025.
- Annual changes were most pronounced in 2023 — Total Non-Current Liabilities surged 342.48% — and 2024, when it sank 92.23%.
- Adlai Nortye's Total Non-Current Liabilities stood at $1.2 million in 2022, then soared by 342.48% to $5.5 million in 2023, then tumbled by 92.23% to $425000.0 in 2024, then surged by 165.18% to $1.1 million in 2025.
- Business Quant data shows ANL's Total Non-Current Liabilities at $1.1 million in Q4 2025, $257000.0 in Q2 2025, and $425000.0 in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 3.92 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 1.53 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 1.88 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 4.20 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 9.32 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Adlai Nortye | 500.08 Mn | 268.19 Mn | - | 8.31 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 8.31 Mn |
| Dec 31, 2025 | 1.13 Mn |
| Jun 30, 2025 | 257,000.00 |
| Dec 31, 2024 | 425,000.00 |
| Dec 31, 2023 | 5.47 Mn |
| Dec 31, 2022 | 1.24 Mn |